Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (...